Alamar Biosciences, Inc.
ALMR Nasdaq
SEC CIK 2104204
Follow Alamar Biosciences
Weekly email: filings, results
Revenue, last quarter
$33.5M
+68.5% vs same quarter last year
Net income
−$13.3M
−66.8% vs same quarter last year
EPS, diluted
−$0.19
+72.5% vs same quarter last year
Operating cash flow
−$14.7M
−4.2% vs same quarter last year
Source: SEC XBRL filings · latest filing